Citing the voluntary recall of its certain infant formula products, medical devices and healthcare company, Abbott Laboratories (NYSE: ABT) lowered its full-year organic sales growth guidance during the Q1 conference call.  For context, Abbott voluntarily recalled some of its infant formula products (including Similac, Alimentum, and EleCare) earlier this year manufactured at its facility in Sturgis, Michigan.  The action came after the U.S. FDA (Food and Drug Administration) warned consumers not to use specific infant products from Abbott following cases of Cronobacter in four infants who consumed the products produced at the Sturgis plant.
https://www.tipranks.com/news/article/how-will-baby-formula-shortage-affect-abbott?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Mai 2022 bis Jun 2022 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Jun 2021 bis Jun 2022 Click Here for more Abbott Laboratories Charts.